Cramer: Neutral on MannKind's (MNKD) Afrezza

NEW YORK (TheStreet) -- TheStreet's Jim Cramer says MannKind  (MNKD) is difficult to gauge because many people felt its inhaled insulin drug Afrezza would fail. As a result, 28% of the float was short and any positive news would send the stock upward.

Cramer says some believe the stock will go down again almost immediately. On the other hand, those who believe in the drug say this is the beginning of a major move for the stock because Mannkind has already spent so much money trying to get Afrezza developed. 

Cramer remains "completely neutral" on this because "sometimes it's just better to admit that you don't know where something's going."

Must Read: Mannkind Afrezza FDA Panel Epilogue Plus a Mea Culpa

Must Watch: Jim Cramer is Neutral on Mannkind's Afrezza Inhaled Insulin

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MNKD Chart

MNKD data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Facebook Sends Facial Recognition Notification in Error

Facebook Sends Facial Recognition Notification in Error

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists